Fed. Circ. Revives Astellas Patent Axed As Natural Law

By Ryan Davis · September 18, 2024, 9:29 PM EDT

The Federal Circuit on Wednesday vacated a lower court's invalidation of an Astellas Pharma overactive bladder medication patent for claiming only a natural law, saying the holding was improper because the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Astellas Pharma, Inc. v. Sandoz Inc.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

June 16, 2023

Recent Articles By Ryan

November 21, 2024
In Tight Vote, Senate Panel OKs Bill To Set New PTAB Limits
October 28, 2024
Judge Leaves Patent Case After Fed. Circ. Undoes Ruling
October 18, 2024
What Attorneys Expect From Harris And Trump On Patents
October 07, 2024
High Court Rejects Pleas To Hear 7 Patent Cases
September 26, 2024
Senate Patent Bill Markups Delayed Until After Election
August 20, 2024
Vax Patent Battles Heat Up As Attention On Pandemic Wanes
June 21, 2024
Drugmakers Decline To Drop Patent Listings After FTC Letters
April 04, 2024
Microsoft Unit Gets Fed. Circ. Alice Win On Imaging Patents
March 06, 2024
CBP Details Apple Watch Redesign OK In Masimo Patent Row
March 04, 2024
WTO Conference Ends Without COVID IP Waiver Expansion